<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM12702</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-12702</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Studies</subject></subj-group></article-categories><title-group><article-title>Повышенный уровень гликированного гемоглобина (HbA1c) у больных с COVID-19 является маркером тяжести течения инфекции, но не индикатором предшествующего сахарного диабета</article-title><trans-title-group xml:lang="en"><trans-title>High level of glycated hemoglobin (HbA1c) in patients with COVID-19 is a marker of the severity of the infection but not an indicator of previous diabetes mellitus</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5057-127X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестакова</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestakova</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шестакова Марина Владимировна, д.м.н., профессор, академик РАН; eLibrary SPIN: 7584-7015</p><p>Москва</p></bio><bio xml:lang="en"><p>Marina V. Shestakova, MD, PhD, Professor; eLibrary SPIN: 7584-7015Moscow</p></bio><email xlink:type="simple">nephro@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4929-1526</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кононенко</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kononenko</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кононенко Ирина Владимировна, к.м.н., в.н.с.; eLibrary SPIN 6528-7986</p><p>Москва</p></bio><bio xml:lang="en"><p>Irina V. Kononenko, MD, PhD, leading research associate; eLibrary SPIN 6528-7986Moscow</p></bio><email xlink:type="simple">shakhtarina@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2612-5253</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калмыкова</surname><given-names>З. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalmykova</surname><given-names>Z. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Калмыкова Зиля Асхатовна, аспирант; eLibrary SPIN: 1264-0320</p><p>117036 Москва, ул. Дм. Ульянова, д. 11</p></bio><bio xml:lang="en"><p>Zilya. A. Kalmykovа, MD, PhD student; eLibrary SPIN: 1264-032011 Dm. Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">zilya.kalmykova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9524-0124</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Железнякова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheleznyakova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Железнякова Анна Викторовна, к.м.н.; eLibrary SPIN: 8102-1779</p><p>Москва</p></bio><bio xml:lang="en"><p>Anna V. Zheleznyakova, MD, PhD; eLibrary SPIN: 8102-1779Moscow</p></bio><email xlink:type="simple">azhelez@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокрышева</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrysheva</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мокрышева Наталья Георгиевна, д.м.н., профессор, член-корр. РАН; eLibrary SPIN: 5624-3875</p><p>Москва</p></bio><bio xml:lang="en"><p>Natalia G. Mokrysheva, MD, PhD, Professor; eLibrary SPIN: 5624-3875Moscow</p></bio><email xlink:type="simple">nm70@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр эндокринологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>01</month><year>2021</year></pub-date><volume>23</volume><issue>6</issue><fpage>504</fpage><lpage>513</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шестакова М.В., Кононенко И.В., Калмыкова З.А., Железнякова А.В., Мокрышева Н.Г., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Шестакова М.В., Кононенко И.В., Калмыкова З.А., Железнякова А.В., Мокрышева Н.Г.</copyright-holder><copyright-holder xml:lang="en">Shestakova M.V., Kononenko I.V., Kalmykova Z.A., Zheleznyakova A.V., Mokrysheva N.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/12702">https://www.dia-endojournals.ru/jour/article/view/12702</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Прошло менее года с начала пандемии новой коронавирусной инфекции COVID-19, вызванной вирусом SARS-CoV-2. Первые опубликованные результаты исследований демонстрируют частое повышение показателей гликемии у пациентов без предшествующих нарушений углеводного обмена, обсуждается связь состояния углеводного обмена и течения COVID-19.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Выявить частоту ранее установленного и впервые выявленного сахарного диабета (СД) у пациентов, госпитализированных в связи с COVID-19. Оценить взаимосвязь уровня гликированного гемоглобина (HbA1c) с маркерами воспалительного процесса и тяжестью инфекционного заболевания.</p></sec><sec><title>МЕТОДЫ</title><p>МЕТОДЫ. В одноцентровое одномоментное ретроспективное исследование были включены 155 пациентов, госпитализированных в ФГБУ «НМИЦ эндокринологии» МЗ РФ с клинико-лабораторной картиной COVID-19 и двусторонней полисегментарной вирусной пневмонией. Для диагностики нарушений углеводного обмена всем больным проводилось определение глюкозы крови при поступлении (ГКПП), глюкозы плазмы натощак (ГПН) и гликированного гемоглобина (HbA1c). В зависимости от наличия СД в анамнезе пациенты были разделены на 2 группы: 1) без ранее установленного СД и 2) с СД в анамнезе (Группа D). Пациенты без СД в анамнезе по уровню HbA1c были подразделены на подгруппы: с HbA1c ≤6,0% (Группа А), с HbA1c &gt;6,0% и &lt;6,5% (Группа В), с HbA1c ≥6,5% (Группа С). Дополнительно у всех пациентов оценивали маркеры воспаления (скорость оседания эритроцитов (СОЭ), С- реактивный белок (СРБ), интерлейкин-6 (ИЛ-6)), степень поражения легочной ткани по данным компьютерной томографии легких, степени насыщения крови кислородом (SpO2) по данным пульсоксиметрии, длительность госпитализации, исходы лечения.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Больные с ранее установленным диагнозом СД 2 типа (СД2) составили 16,7% (n=26). Из пациентов без СД в анамнезе по совокупности показателей НbA1c , ГПН и ГКПП впервые диагноз СД2 был установлен у 8 больных (5,2%), у 66 больных (42,6%) все три показателя соответствовали нормальным значениям углеводного обмена. У остальных больных (n=55) интерпретация состояния углеводного обмена была затруднена в связи с обнаруженным фактом несоответствия уровня HbA1c показателям ГПН и ГКПП: в частности, уровень HbA1c ≥6,5% (что соответствует диагностическому порогу СД) был выявлен у 19 больных (12,2%) при нормальных показателях ГПН и ГКПП. Стрессовой гипергликемии при поступлении и по состоянию гликемии натощак зарегистрировано не было. Вне зависимости от наличия подтвержденного СД отмечалась значимая положительная корреляция уровня HbA 1c с маркерами воспаления (СОЭ, СРБ, ИЛ-6) и отрицательная — со степенью сатурации кислорода (SpO2). Пациенты с HbA1c ≥6,5% без СД в анамнезе имели наиболее тяжелое течение заболевания: самую большую длительность госпитализации, наибольшее поражение легочной ткани, высокую летальность.</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Частота СД среди госпитализированных с COVID-19 больных составила 21,9% (из них у 16,7% диагноз СД был установлен ранее, у 5,2% — выявлен впервые). Это в 1,5 раза выше, чем в общей популяции в сопоставимой возрастной категории. У пациентов без СД в анамнезе диагностика нарушений углеводного обмена в остром инфекционном периоде затруднена. Повышенный уровень HbA1c (≥6,5%), впервые выявленный в остром периоде инфекции, в сочетании с нормальными показателями ГПН и при ГКПП не может являться диагностическим критерием СД и требует динамического наблюдения. Уровень HbA1c вне зависимости от наличия СД может рассматриваться как прогностический фактор в отношении тяжести новой коронавирусной инфекции.</p></sec></abstract><trans-abstract xml:lang="en"><p>BACKGROUND: Less than a year has passed since the start of the new coronavirus infection COVID-19 pandemic caused by SARS-CoV-2. First published research results demonstrate a frequent increase in glycemia in patients without previously diagnosed carbohydrate metabolism disorders. A possible relationship between the carbohydrate metabolism state and the course of COVID-19 is considered.AIM: To identify the incidence of known and newly diagnosed diabetes mellitus (DM) in hospitalized patients with COVID-19 and evaluate the relationship between glycated hemoglobin (HbA1c), inflammation markers and infectious disease severity.METHODS: A single-center, cross-sectional, retrospective study included 155 patients with confirmed COVID-19 and bi- lateral polysegmental viral pneumonia hospitalized in the Endocrinology Research Centre, Russian Federation. Diagnosis of carbohydrate metabolism disorders was based on the HbA1c level, blood glucose level at admission (BGA) and fasting plasma glucose (FPG). Patients were divided into 2 groups: without the previously diagnosed DM (n=129, 83.3%) and with known history of DM (n=26, 16,7%). Patients without previously diagnosed DM were divided into subgroups according to HbA1c levels: ≤6,0% (Group A), &gt;6,0% HbA1c, &lt;6.5% (Group B), ≥6,5% (Group C). Additionally, insulin, interleukin 6 (IL-6) and D-dimer levels were measured in all patients. Blood oxygen saturation (SpO2) was measured by pulsoximetry, computerized tomography of lungs with calculation of lung parenchyma damage percentage.RESULTS: Type 2 DM was previously established in 16.7% of all included patients. Among patients without DM history, DM was revealed in 8 patients (5.2%), based on HbA1c, FPG and BGA. In 66 patients (42.6%) we observed no changes in carbohydrate metabolism. In 55 patients, the interpretation of carbohydrate metabolism state was difficult due to inconsistency of HbA1c level with FPG and BGA: in particular, the level of HbA1c ≥ 6.5% (which corresponds to the diagnostic threshold of the DM) was detected in 19 patients (12,2%) with normal FPG and BGA. No true stress hyperglycemia on admission and according to FPG was reported. Despite the presence of confirmed DM, HbA1c levels positively correlated with inflammatory markers (erythro- cyte sedimentation rate, C-reactive protein, IL-6) and SpO2. Patients with a HbA1c ≥6.5% without DM history had the most severe course of the disease: longest duration of hospitalization, largest damage of the pulmonary tissue, and high lethality.CONCLUSION: The incidence of DM among patients hospitalized with COVID-19 was 21.9% (16.7% had previous diagnosis of DM, 5.2% — newly diagnosed), which is 1.5 times higher than in general population in a comparable age category. It is difficult to assess the carbohydrate metabolism disorders in patients in acute infectious period. An increased level of HbA1c (≥6.5%), first detected in the acute period of infection, in combination with normal FPG and BGA parameters, cannot be a diagnostic criterion and requires dynamic monitoring. HbA1c level can be considered as a predictive factor of COVID-19 severity, independent of DM.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>сахарный диабет</kwd><kwd>стресс-индуцированная гипергликемия</kwd><kwd>HbA1c</kwd><kwd>маркеры воспаления</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>stress hyperglycemia</kwd><kwd>HbA1c</kwd><kwd>inflammation markers</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено за счет гранта Минобрнауки РФ (соглашение № 075-15-2020-899).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">World Health Organization. [Internet]. Coronavirus disease (COVID-2019) situation reports. [cited 2020 May 30]. Доступно по ссылке: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</mixed-citation><mixed-citation xml:lang="en">World Health Organization. [Internet]. Coronavirus disease (COVID-2019) situation reports. [cited 2020 May 30]. Доступно по ссылке: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052</mixed-citation><mixed-citation xml:lang="en">Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):303-310. doi: 10.1016/j.dsx.2020.04.004</mixed-citation><mixed-citation xml:lang="en">Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr Clin Res Rev. 2020;14(4):303-310. doi: 10.1016/j.dsx.2020.04.004</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi: 10.1177/1932296820924469</mixed-citation><mixed-citation xml:lang="en">Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi: 10.1177/1932296820924469</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Thaweerat W. Current evidence on pancreatic involvement in SARS-CoV-2 infection. Pancreatology. 2020;20(5):1013-1014. doi: 10.1016/j.pan.2020.05.015</mixed-citation><mixed-citation xml:lang="en">Thaweerat W. Current evidence on pancreatic involvement in SARS-CoV-2 infection. Pancreatology. 2020;20(5):1013-1014. doi: 10.1016/j.pan.2020.05.015</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liao W-I, Wang J-C, Chang W-C, et al. Usefulness of Glycemic Gap to Predict ICU Mortality in Critically Ill Patients With Diabetes. Medicine (Baltimore). 2015;94(36):e1525. doi: 10.1097/MD.0000000000001525</mixed-citation><mixed-citation xml:lang="en">Liao W-I, Wang J-C, Chang W-C, et al. Usefulness of Glycemic Gap to Predict ICU Mortality in Critically Ill Patients With Diabetes. Medicine (Baltimore). 2015;94(36):e1525. doi: 10.1097/MD.0000000000001525</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Falciglia M, Freyberg RW, Almenoff PL, et al. Hyperglycemia–related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37(12):3001-3009. doi: 10.1097/CCM.0b013e3181b083f7</mixed-citation><mixed-citation xml:lang="en">Falciglia M, Freyberg RW, Almenoff PL, et al. Hyperglycemia–related mortality in critically ill patients varies with admission diagnosis. Crit Care Med. 2009;37(12):3001-3009. doi: 10.1097/CCM.0b013e3181b083f7</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Cormio M, Barile L, Citerio G, et al. Feasibility and advantages of normothermia in patients with acute cerebral damage: preliminary results of a prospective randomised study. Crit Care. 2001;5(Suppl 1):P184. doi: 10.1186/cc1251</mixed-citation><mixed-citation xml:lang="en">Cormio M, Barile L, Citerio G, et al. Feasibility and advantages of normothermia in patients with acute cerebral damage: preliminary results of a prospective randomised study. Crit Care. 2001;5(Suppl 1):P184. doi: 10.1186/cc1251</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">National Health Service (NHS) England. [Internet] Resources to support the safe adoption of the revised National Early Warning Score (NEWS2). [cited 2020 May 5]. Доступно по ссылке: www.england.nhs.uk/wp-content/uploads/2019/12/Patient_Safety_Alert_-_adoption_of_NEWS2.pdf</mixed-citation><mixed-citation xml:lang="en">National Health Service (NHS) England. [Internet] Resources to support the safe adoption of the revised National Early Warning Score (NEWS2). [cited 2020 May 5]. Доступно по ссылке: www.england.nhs.uk/wp-content/uploads/2019/12/Patient_Safety_Alert_-_adoption_of_NEWS2.pdf</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">American diabetes association: diabetes statistics. [Internet] [cited 2020 May 5]. Доступно по ссылке: https://www.diabetes.org/resources/statistics/statistics-about-diabetes</mixed-citation><mixed-citation xml:lang="en">American diabetes association: diabetes statistics. [Internet] [cited 2020 May 5]. Доступно по ссылке: https://www.diabetes.org/resources/statistics/statistics-about-diabetes</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Greci LS, Kailasam M, Malkani S, et al. Utility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients With Hyperglycemia. Diabetes Care. 2003;26(4):1064-1068. doi: 10.2337/diacare.26.4.1064</mixed-citation><mixed-citation xml:lang="en">Greci LS, Kailasam M, Malkani S, et al. Utility of HbA1c Levels for Diabetes Case Finding in Hospitalized Patients With Hyperglycemia. Diabetes Care. 2003;26(4):1064-1068. doi: 10.2337/diacare.26.4.1064</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rau C-S, Wu S-C, Chen Y-C, et al. Stress-Induced Hyperglycemia in Diabetes: A Cross-Sectional Analysis to Explore the Definition Based on the Trauma Registry Data. Int J Environ Res Public Health. 2017;14(12):1527. doi: 10.3390/ijerph14121527</mixed-citation><mixed-citation xml:lang="en">Rau C-S, Wu S-C, Chen Y-C, et al. Stress-Induced Hyperglycemia in Diabetes: A Cross-Sectional Analysis to Explore the Definition Based on the Trauma Registry Data. Int J Environ Res Public Health. 2017;14(12):1527. doi: 10.3390/ijerph14121527</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Глыбочко П.В., Фомин В.В., Авдеев С.Н., и др. Клиническая характеристика 1007 больных тяжелой SARS-CoV-2 пневмонией, нуждавшихся в респираторной поддержке // Клин Фармакол Тер. — 2020. — Т. 29. — No2. — С. 21-29. doi: 10.32756/0869-5490-2020-2-21-29</mixed-citation><mixed-citation xml:lang="en">Glybochko PV, Fomin VV, Avdeev SN, et al. Clinical characteristics of 1007 patients with severe SARS-CoV-2 pneumonia who needed respiratory support. Clin Pharmacol Ther. 2020;29(2):21-29 (In Russ.). doi: 10.32756/0869-5490-2020-2-21-29</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова М.В., Дедов И.И. Сахарный диабет в Российской Федерации: аргументы и факты // Терапевтический архив. — 2016. — Т. 88. — No10. — С. 4-8. doi: 10.17116/terarkh201688104-8</mixed-citation><mixed-citation xml:lang="en">Shestakova MV, Dedov II. Diabetes mellitus in the Russian Federation: Arguments and facts. Ter Arkh. 2016;88(10):4-8. (In Russ.). doi: 10.17116/terarkh201688104-8</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006</mixed-citation><mixed-citation xml:lang="en">Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. doi: 10.1016/j.jaci.2020.04.006</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ceriello A. Hyperglycemia and COVID-19: What was known and what is really new? Diabetes Res Clin Pract. 2020;167(1):108383. doi: 10.1016/j.diabres.2020.108383</mixed-citation><mixed-citation xml:lang="en">Ceriello A. Hyperglycemia and COVID-19: What was known and what is really new? Diabetes Res Clin Pract. 2020;167(1):108383. doi: 10.1016/j.diabres.2020.108383</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020;164(1):108166. doi: 10.1016/j.diabres.2020.108166</mixed-citation><mixed-citation xml:lang="en">Chee YJ, Ng SJH, Yeoh E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract. 2020;164(1):108166. doi: 10.1016/j.diabres.2020.108166</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Chee YJ, Ng SJH, Yeoh E. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009;32(7):1327-1334. doi: h10.2337/dc09-9033</mixed-citation><mixed-citation xml:lang="en">Chee YJ, Ng SJH, Yeoh E. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009;32(7):1327-1334. doi: h10.2337/dc09-9033</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97(1):16-38. doi: 10.1210/jc.2011-2098</mixed-citation><mixed-citation xml:lang="en">Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2012;97(1):16-38. doi: 10.1210/jc.2011-2098</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated Admission Glucose and Mortality in Elderly Patients Hospitalized With Heart Failure. Circulation. 2009;119(14):1899-1907. doi: 10.1161/CIRCULATIONAHA.108.821843</mixed-citation><mixed-citation xml:lang="en">Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated Admission Glucose and Mortality in Elderly Patients Hospitalized With Heart Failure. Circulation. 2009;119(14):1899-1907. doi: 10.1161/CIRCULATIONAHA.108.821843</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020;167(14):108382. doi: 10.1016/j.diabres.2020.108382</mixed-citation><mixed-citation xml:lang="en">Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract. 2020;167(14):108382. doi: 10.1016/j.diabres.2020.108382</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Mohan V, Unnikrishnan R, Anjana R. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528. doi: 10.4103/2230-8210.98004</mixed-citation><mixed-citation xml:lang="en">Mohan V, Unnikrishnan R, Anjana R. Drugs affecting HbA1c levels. Indian J Endocrinol Metab. 2012;16(4):528. doi: 10.4103/2230-8210.98004</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Giugliano D. Increased glycosylated haemoglobin A1 in opiate addicts: Evidence for a hyperglycaemic effect of morphine. Diabetologia. 1982;22(5):528. doi: 10.1007/BF00253587</mixed-citation><mixed-citation xml:lang="en">Giugliano D. Increased glycosylated haemoglobin A1 in opiate addicts: Evidence for a hyperglycaemic effect of morphine. Diabetologia. 1982;22(5):528. doi: 10.1007/BF00253587</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Marcovecchio ML. Complications of Acute and Chronic Hyperglycemia. US Endocrinol. 2017;13(01):17. doi: 10.17925/USE.2017.13.01.17</mixed-citation><mixed-citation xml:lang="en">Marcovecchio ML. Complications of Acute and Chronic Hyperglycemia. US Endocrinol. 2017;13(01):17. doi: 10.17925/USE.2017.13.01.17</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020;164(01):108214. doi: 10.1016/j.diabres.2020.108214</mixed-citation><mixed-citation xml:lang="en">Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020;164(01):108214. doi: 10.1016/j.diabres.2020.108214</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Smith SM, Boppana A, Traupman JA, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19. J Med Virol. 2021;93(1):409-415. doi: 10.1002/jmv.26227</mixed-citation><mixed-citation xml:lang="en">Smith SM, Boppana A, Traupman JA, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID‐19. J Med Virol. 2021;93(1):409-415. doi: 10.1002/jmv.26227</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi: 10.1177/1932296820924469</mixed-citation><mixed-citation xml:lang="en">Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi: 10.1177/1932296820924469</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Wenzhong L, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. 2020. doi: 10.26434/chemrxiv.11938173.v4.</mixed-citation><mixed-citation xml:lang="en">Wenzhong L, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. ChemRxiv. 2020. doi: 10.26434/chemrxiv.11938173.v4.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Арутюнов Г.П., Козиолова Н.А., Тарловская Е.И., и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по некоторым новым механизмам патогенеза COVID-19: фокус на гемостаз, вопросы гемотрансфузии и систему транспорта газов крови // Кардиология. — 2020. — Т. 60. — No5. — С. 9-19. doi: 10.18087/cardio.2020.5.n1132</mixed-citation><mixed-citation xml:lang="en">Arutyunov GP, Koziolova NA, Tarlovskaya EI, et al. The Agreed Experts’ Position of the Eurasian Association of Therapists on Some new Mechanisms of COVID-19 Pathways: Focus on Hemostasis, Hemotransfusion Issues and Blood gas Exchange. Kardiologiia. 2020;60(5):9-19 (In Russ.). doi: 10.18087/cardio.2020.5.n1132</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cosic I, Cosic D, Loncarevic I. RRM Prediction of Erythrocyte Band3 Protein as Alternative Receptor for SARS-CoV-2 Virus. Appl Sci. 2020;10(11):4053. doi: 10.3390/app10114053</mixed-citation><mixed-citation xml:lang="en">Cosic I, Cosic D, Loncarevic I. RRM Prediction of Erythrocyte Band3 Protein as Alternative Receptor for SARS-CoV-2 Virus. Appl Sci. 2020;10(11):4053. doi: 10.3390/app10114053</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sathish T, Mello GT, Cao Y. Is newly diagnosed diabetes a stronger risk factor then pre-existing diabetes for COVID-19 severity? J Diabetes. 2021;13(2):177-178. doi: 10.1111/1753-0407.13125</mixed-citation><mixed-citation xml:lang="en">Sathish T, Mello GT, Cao Y. Is newly diagnosed diabetes a stronger risk factor then pre-existing diabetes for COVID-19 severity? J Diabetes. 2021;13(2):177-178. doi: 10.1111/1753-0407.13125</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
